| abstract |
The present invention is directed to a combination of active agents which allow a targeted inhibition of the mammalian target of rapamycin C1 complex (mTORC1) and its use in the treatment of cancer, depression, neurodegeneration, transplant rejection or metabolic disorders as well as to a FKBP subtype-specific rapamycin analogue selective for a single FKBP, wherein the FKBP subtype-specific rapamycin analogue preferentially forms a complex with only a single FKBP and this complex binds and/or inhibits the mammalian target of rapamycin for use in treatment of cancer, depression, neurodegeneration, transplant rejection or metabolic disorders. |